Dr. Shami is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
1950 Circle of Hope Dr
Salt Lake City, UT 84112Phone+1 801-581-2121- Is this information wrong?
Education & Training
- Duke University HospitalFellowship, Hematology and Medical Oncology, 1991 - 1994
- Duke University HospitalResidency, Internal Medicine, 1988 - 1991
- American University of Beirut Faculty of MedicineClass of 1988
Certifications & Licensure
- UT State Medical License 1997 - 2026
- NC State Medical License 1991 - 1999
- MD State Medical License 1990 - 1991
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Low-dose Oral Clofarabine for the Treatment of IPSS INT-1, INT-2 or HIGH Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia Start of enrollment: 2008 Mar 01
- Decitabine Maintenance in Elderly Acute Myeloid Leukemia Patients Start of enrollment: 2011 Feb 01
- Feasibility and Outcomes of Allogeneic HCT Compared to Chemotherapy in Older AML Patients Start of enrollment: 2013 Jul 19
- Join now to see all
Publications & Presentations
PubMed
- Obinutuzumab-Based Drug-Free Macromolecular Therapeutics Synergizes with Topoisomerase Inhibitors.M Tommy Gambles, Douglas Sborov, Paul Shami, Jiyuan Yang, Jindřich Kopeček> ;Macromolecular Bioscience. 2024 Mar 1
- 12 citationsNorth American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of need.Naveen Pemmaraju, Hagop Kantarjian, Kendra Sweet, Eunice Wang, Jayastu Senapati, Nathaniel R Wilson, Marina Konopleva, Arthur E Frankel, Vikas Gupta, Ruben Mesa, Matth...> ;Blood. 2023 Feb 9
- 5 citationsAn 8-year pragmatic observation evaluation of the benefits of allogeneic HCT in older and medically infirm patients with AML.Mohamed L Sorror, Ted A Gooley, Barry E Storer, Aaron T Gerds, Mikkael A Sekeres, Bruno C Medeiros, Eunice S Wang, Paul J Shami, Kehinde Adekola, Selina Luger, Maria R...> ;Blood. 2023 Jan 19
- Join now to see all
Abstracts/Posters
- Prevalence of Inherited Cancer Predisposition Mutations in a Cohort of Older AML Patients Enrolled on the Beat AML Master TrialPaul J Shami, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Lectures
- Limitations to Receiving Allogeneic Hematopoietic Cell Transplantation for Treatment of Acute Myeloid Leukemia: A Large Multi-Center Prospective Longitudinal Observati...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Survival Differences Among Patients (pts) with Acute Myeloid Leukemia (AML) Treated with Allogeneic Hematopoietic Cell Transplantation (HCT) Versus Non-HCT Therapies: ...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Press Mentions
- Durham’s Chimerix Pays $30M to Secure Rights for Late-Stage Leukemia DrugAugust 2nd, 2019
- Chimerix Announces Exclusive Worldwide License of Phase 3 Ready CX-01 for Development in Acute Myeloid LeukemiaJuly 31st, 2019
- Huntsman Cancer Institute Joins Study Aimed at Improving Leukemia Screening, TreatmentMarch 19th, 2018
- Join now to see all
Grant Support
- Preclinical Development Of JS-K, A Novel No-Generating Prodrug For CancerNational Cancer Institute2010–2012
- Development Of JS-K As An Anti-Leukemic AgentNational Cancer Institute2008–2012
- Role Of Nitric Oxide In Myelodysplastic SyndromesNational Center For Research Resources2005
- Genetic Targets Of Nitric Oxide In Leukemia CellsNational Cancer Institute2002–2004
- NO, Guanylate Cyclase And Immunotherapy Of CancerNational Cancer Institute2000
Professional Memberships
- Member
Hospital Affiliations
- University of Utah HealthSalt Lake City, Utah
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: